Biogen Inc. (Biogen), a global biopharmaceutical company, focuses on discovering, developing and delivering innovative therapies for people living with serious and complex diseases.
The company has a broad portfolio of medicines to treat MS, has int…
Analysis
Bargain bin
Biogen Inc. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.
On valuation, the picture is attractive. The owner-earnings multiple stands at 14.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 2% a year, against analyst forecasts of 2%. The price, in other words, assumes less than the experts do.
Growth is tepid; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Feb 202673
60
2026
All-time high
73
Feb 2026
All-time low
54
Mar 2026
Average rank
62
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
89
—
—
—
Price/Earnings
20
—
—
—
Price/Book
69
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
66
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.